Status:
COMPLETED
Short-term Effect of Intensive Insulin Therapy on Incretin Secretion
Lead Sponsor:
The Catholic University of Korea
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
20-70 years
Brief Summary
In type 2 diabetic patients, abnormality in secretion or action of incretin(GLP-1, GIP) is observed. Although controversy still exists, the secretion of GLP-1 is thought to be reduced by 20-30% while ...
Eligibility Criteria
Inclusion
- type 2 diabetic patients with disease duration of less than 15years
- age of 20-70 years
- BMI 22-27
- HbA1c 9-13%
- patients willing to receive intensive glucose control
- patients who are able to monitor their glucose level at home
- for normal glucose tolerance group : NGT subjects with same range of age and BMI
- for early diabetes group : patients with diabetic duration of less than 5 years and HbA1c level less than 7.5% for at least last 6 months
Exclusion
- previous history of insulin treatment
- patients taking alpha-glucosidase inhibitor or thiazolidinedione
- serum creatinine \>= 1.5 mg/dL
- hemoglobin \< 10 g/dL
- AST/ALT greater than 3 times normal range
- ischemic heart disease, congestive heart failure (NYHA grade \>=2)
- chronic renal failure, proliferative diabetic retinopathy, CVA
- patients with gastroparesis or taking medications altering gastric motility
- usage of steroid or other agents affecting glucose metabolism
- pregnant or breast-feeding women
Key Trial Info
Start Date :
October 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2009
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00776243
Start Date
October 1 2008
End Date
December 1 2009
Last Update
May 12 2010
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Division of Endocrinology and Metabolism, St.Vincent's Hospital
Suwon, Kyonggi-do, South Korea, 442-723
2
Division of Endocrinology and Metabolism, Kangnam St.Mary's Hospital
Seoul, South Korea, 137-701